This is a StreetInsider.com Premium Only Page

(PHVS) – StreetInsider.com Reports

Apr 11, 2024 03:03 AM Pharvaris B.V. (PHVS) PT Raised to $50 at JMP Securities

Apr 10, 2024 04:09 PM Pharvaris (PHVS) Appoints David Nassif, J.D., as Chief Financial Officer

Mar 6, 2024 04:43 PM Pharvaris (PHVS) Files for 5.55M Share Offering by Selling Stockholders

Feb 22, 2024 06:50 AM Pharvaris (PHVS) Reports Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant

Jan 23, 2024 03:02 AM Pharvaris B.V. (PHVS) PT Raised to $49 at JMP Securities

Jan 22, 2024 06:50 AM Pharvaris (PHVS) Announces FDA Lifting of the Clinical Hold of Deucrictibant

Jan 5, 2024 06:50 AM Pharvaris (PHVS) Provides Business Update, Outlines 2024 Strategic Priorities

Dec 11, 2023 04:12 AM Pharvaris (PHVS) Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE

Dec 7, 2023 07:58 AM Pharvaris B.V. (PHVS) PT Raised to $35 at Morgan Stanley

Dec 7, 2023 04:56 AM Pharvaris B.V. (PHVS) PT Raised to $11 at BofA Securities

Dec 6, 2023 03:55 PM Pharvaris B.V. (PHVS) PT Raised to $36 at Oppenheimer

Dec 6, 2023 06:52 AM Pharvaris (PHVS) Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Nov 15, 2023 06:50 AM Pharvaris (PHVS) Appoints Stefan Abele as Chief Technical Operations Officer

Nov 14, 2023 08:19 AM Pharvaris B.V. (PHVS) PT Lowered to $32 at Morgan Stanley

Sep 25, 2023 06:53 AM Wedbush Starts Pharvaris B.V. (PHVS) at Outperform

Aug 15, 2023 08:57 AM Pharvaris B.V. (PHVS) PT Raised to $34 at Morgan Stanley

Aug 15, 2023 12:54 AM Morgan Stanley Upgrades Pharvaris B.V. (PHVS) to Overweight

Aug 7, 2023 03:20 PM Pharvaris N.V. (PHVS) Tops Q2 EPS by 2c

Jun 27, 2023 08:10 AM Pharvaris B.V. (PHVS) PT Raised to $26 at Oppenheimer

Jun 20, 2023 06:53 AM Pharvaris (PHVS) Announces $70M Private Placement

Apr 6, 2023 03:29 AM Pharvaris B.V. (PHVS) PT Lowered to $20 at JMP Securities

Mar 20, 2023 05:58 AM Pharvaris (PHVS) Presents Positive Phase 2 Data from RAPIDe-1 Study of PHVS416

Feb 24, 2023 06:50 AM Pharvaris (PHVS) to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416

Jan 11, 2023 02:17 AM Pharvaris B.V. (PHVS) PT Raised to $23 at JMP Securities

Jan 9, 2023 06:53 AM Pharvaris (PHVS) Provides Regulatory, Clinical, and Corporate Updates

Dec 9, 2022 09:27 AM Pharvaris B.V. (PHVS) PT Raised to $8 at BofA Securities

Dec 9, 2022 08:42 AM Pharvaris B.V. (PHVS) PT Raised to $24 at Oppenheimer

Dec 8, 2022 04:34 PM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.55%

Dec 8, 2022 12:26 PM Pharvaris (PHVS) Halted Again on Volatility, Up 226%

Dec 8, 2022 09:56 AM Pharvaris (PHVS) Extends Gain Following Data, Up 96%

Dec 8, 2022 07:06 AM Pharvaris (PHVS) Phase 2 Data from RAPIDe-1 Study of PHVS416 for On-Demand Treatment of HAE Attacks Shows Statistically Significant Results

Oct 7, 2022 08:31 AM Pharvaris (PHVS) Presents Data Supporting HAE Drug Development Strategy

Oct 3, 2022 04:40 PM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.66%

Sep 16, 2022 05:55 AM Pharvaris (PHVS) Highlights Data Supporting Clinical Development Program for Hereditary Angioedema

Sep 13, 2022 04:45 PM Pharvaris B.V. (PHVS) PT Lowered to $20 at SVB Leerink

Sep 13, 2022 03:41 AM JMP Securities Reinstates Pharvaris B.V. (PHVS) at Market Outperform

Sep 12, 2022 06:52 AM Pharvaris (PHVS) Reports Q2 Results, Provides Business Update

Aug 23, 2022 06:45 AM Pharvaris B.V. (PHVS) PT Lowered to $25 at SVB Leerink

Aug 23, 2022 05:07 AM UPDATE: Morgan Stanley Downgrades Pharvaris B.V. (PHVS) to Equalweight

Aug 22, 2022 05:29 PM Pharvaris B.V. (PHVS) PT Lowered to $22 at Oppenheimer

Aug 22, 2022 10:48 AM BofA Securities Downgrades Pharvaris B.V. (PHVS) to Underperform

Aug 22, 2022 06:51 AM Pharvaris (PHVS) Announces FDA Clinical Hold on PHA121 Trials

Jul 6, 2022 09:14 AM Pharvaris B.V. (PHVS) 4Q22 Readouts Are Likely a Positive Catalyst - Oppenheimer

May 25, 2022 03:18 AM JMP Securities Starts Pharvaris B.V. (PHVS) at Market Outperform

May 11, 2022 08:11 AM Pharvaris (PHVS) Reports Q1 EPS of EUR ($0.48), Provides Business Highlights

Mar 22, 2022 08:10 AM Pharvaris (PHVS) Announces Publication of Pharmacological Data for Small Molecule PHA121

Dec 22, 2021 08:12 AM Pharvaris (PHVS) Announces Changes to its Board of Directors

Dec 7, 2021 08:10 AM Pharvaris (PHVS) Appoints Elisabeth Bjork to its Board, Announces Resignation of Martijn Kleijwegt

Aug 4, 2021 05:30 AM Pharvaris B.V. (PHVS) PT Lowered to $21 at BofA Securities

Apr 21, 2021 08:12 AM Pharvaris (PHVS) Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416